Identification of ENV determinants in V3 that influence the molecular anatomy of CCR5 utilization

Journal of Molecular Biology

Volumn 302, Issue 2, 2000, Pages 359-375

  Hu, Qin Xue ^a   Trent, John O ^a   Tomaras, Georgia D ^b   Wang, Zi Xuan ^a   Murray, James L ^a   Conolly, Shannon M ^b   Navenot, Jean Marc ^a   Barry, Ashley Perkins ^b   Greenberg, Michael L ^b   Peiper, Stephen C ^a  

^a UNIVERSITY OF LOUISVILLE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Envelope structure; HIV 1; Tropism; Virus coreceptor

Indexed keywords

ALANINE; CHEMOKINE RECEPTOR CCR5; GLYCOPROTEIN GP 120; PROLINE; VASOPRESSIN V3 RECEPTOR;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR CLONING; MOLECULAR DYNAMICS; MOLECULAR MODEL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN INTERACTION; PROTEIN STRUCTURE; SITE DIRECTED MUTAGENESIS; VIRUS ENVELOPE;

EID: 0034665636     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1006/jmbi.2000.4076     Document Type: Article

References (71)

1. CC CKR5: A RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophagetropic HIV-1
2. HIV and SIV gp120 binding does not predict coreceptor function
3. A new classification for HIV-1
4. HIV-1-induced cell fusion is mediated by multiple regions within both the viral envelope and the CCR-5 co-receptor
5. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype
6. Multiple charged and aromatic residues in CCR5 amino-terminal domain are involved in high-affinity binding of both chemokines and HIV-1 env protein
7. Structure and polymorphism of HIV-1 third variable loops
8. Phenotypic variation in the response to the human immunodeficiency virus among derivatives of the CEM T and WIL-2 B cell lines
9. Solution conformational preferences of immunogenic peptides derived from the principal neutralizing determinant of the HIV-1 envelope glycoprotein gp120
10. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates
11. Direct and indirect estimates of HIV-1 incidence in a high-prevalence population
12. The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection
13. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes
14. A second-generation force field for the simulation of proteins, nucleic acids, and organic molecules
15. High frequency of the GWG (Pro Trp) envelope variant of HIV-1 in Southeast Brazil
16. Identification of a major co-receptor for primary isolates of HIV-1
17. Unwelcomed guests with master keys: How HIV uses chemokine receptors for cellular entry
18. A dual-tropic primary HIV-1 isolate that uses fusion and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors
19. Two distinct CCR5 domains can mediate coreceptor usage by human immunodeficiency virus type 1
20. Use of a gp120 binding assay to dissect the requirements and kinetics of human immunodeficiency virus fusion events
21. Identification of CXCR4 domains that support coreceptor and chemokine receptor functions
22. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC- CKR-5
23. Amino-terminal substitutions in the CCR5 coreceptor impair gp120 binding and human immunodeficiency virus type 1 entry
24. A tyrosine-rich region in the N terminus of CCR5 is important for human immunodeficiency virus type 1 entry and mediates an association between gp120 and CCR5
25. Tyrosine suffation of the amino terminus of CCR5 facilitates HIV-1 entry
26. HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor
27. Crystal structure of the principal neutralization site of HIV-1
28. Structure-based design of a constrained peptide mimic of the HIV-1 V3 loop neutralization site
29. Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees
30. Mutations in the principal neutralization determinant of human immunodeficiency virus type 1 affect syncytium formation, virus infectivity, growth kinetics, and neutralization
31. HIV type I envelope determinants for use of the CCR2b, CCR3, STRL33, and APJ coreceptors
32. Classical electrostatics in biology and chemistry
33. Analysis of the critical domain in the V3 loop of human immunodeficiency virus type 1 gp120 involved in CCR5 utilization
34. Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1
35. Alteration of HIV-1 infectivity and neutralization by a single amino acid replacement in the V3 loop domain
36. V3 loop region of the HIV-1 gp120 envelope protein is essential for virus infectivity
37. Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1
38. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody
39. Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant
40. Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function
41. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection
42. Changing virus-host interactions in the course of HIV-1 infection
43. The role of the V3 loop of gp120 in HIV infection
44. Protein folding and association: Insights from the interfacial and thermodynamic properties of hydrocarbons
45. HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp120 outside the CD4-binding domain
46. Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5
47. Analysis of mutations in the V3 domain of gp160 that affect fusion and infectivity
48. Chimeric chemokine receptors for analysis of structure-function relationships
49. Evolution of envelope sequences from the genital tract and peripheral blood of women infected with clade A human immunodeficiency virus type 1
50. Crystal structure of a human immunodeficiency virus type 1 neutralizing antibody, 50. 1, in complex with its V3 loop peptide antigen
51. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding
52. The ability of HIV type 1 to use CCR-3 as a coreceptor is controlled by envelope V1/V2 sequences acting in conjunction with a CCR-5 tropic V3 loop
53. Regions in beta-chemokine receptors CCR5 and CCR2b that determine HIV-1 cofactor specificity
54. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene
55. The second extracellular loop of CCR5 is the major determinant of ligand specificity
56. Changes in and discrepancies between cell tropisms and coreceptor uses of human immunodeficiency virus type 1 induced by single point mutations at the V3 tip of the env protein
57. Macrophage and T cell-line tropisms of HIV-1 are determined by specific regions of the envelope gp120 gene
58. Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4
59. Determinants of entry cofactor utilization and tropism in a dualtropic human immunodeficiency virus type 1 primary isolate
60. Dual conformations for the HIV-1 gp120 V3 loop in complexes with different neutralizing Fabs
61. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co- receptor CCR-5
62. A cis proline turn linking two beta-hairpin strands in the solution structure of an antibody-bound HIV-1IIIB V3 peptide
63. Evolution of syncytium-inducing and non-syncytium-inducing biological virus clones in relation to replication kinetics during the course of human immunodeficiency virus type 1 infection
64. The complete Consensus V3 loop peptide of the envelope protein gp120 of HIV-1 shows pronounced helical character in solution
65. Nuclear magnetic resonance analysis of solution conformations in C4-V3 hybrid peptides derived from human immunodeficiency virus (HIV) type 1 gp120: Relation to specificity of peptide-induced anti-HIV neutralizing antibodies
66. Hypervariable region 3 residues of HIV type 1 gp120 involved in CCR5 coreceptor utilization: Therapeutic and prophylactic implications
67. CCR5 HIV-1 coreceptor activity. Role of cooperativity between residues in N-terminal extracellular and intracellular domains
68. Identification of a determinant within the human immunodeficiency virus 1 surface envelope glycoprotein critical for productive infection of primary monocytes
69. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5
70. Interaction of chemokine receptor CCR5 with its ligands: Multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding